Shots:

• The US FDA has cleared its IND application to initiate a P-I/II dose-escalation trial of LX2006 given as a one-time IV inf. in patients with FA cardiomyopathy for 52wks. The trial is expected to initiate in mid of 2022
• In preclinical studies, LX2006 can reverse the cardiac abnormalities in FA disease models, improvement in cardiac function and survival & has a favorable safety profile
• LX2006 is an AAV-based gene therapy product & has received RPDD & ODD for FA The therapy was designed to target the cardiac manifestations of FA through the functional frataxin gene to promote the expression of the frataxin protein & restore mitochondrial function in myocardial cells

 Ref: Globe Newswire | Image: Lexeo